Our Vision and Mission
We are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world.
Our mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide.
LEARN MORE>>Technology
We leverage the Trimer-Tag technology platform and our in-house manufacturing and commercial capabilities to develop innovative vaccines.
LEARN MORE>>Pipeline
We have a diverse pipeline of candidates with the potential to make a meaningful difference in improving health around the world.
LEARN MORE>>Response
We are expanding access to our COVID-19 vaccine and continuing to develop next-generation options as part of the ongoing response to COVID-19.
LEARN MORE>>Areas of Focus
Vaccines
Other
Diseases
Latest News
Oct 29, 2024
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY
Jun 18, 2024
Clover Announces Positive Preliminary PhaseⅠResults for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
Apr 8, 2024
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
Dec 29, 2023
Clover Announces Positive PhaseⅠResults for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)